Diabetic nephropathy: A twisted thread to unravel

被引:34
作者
Dagar, Neha [1 ]
Das, Pamelika [2 ]
Bisht, Priya [1 ]
Taraphdar, Amit Kumar [3 ]
Velayutham, Ravichandiran [1 ,2 ]
Arumugam, Somasundaram [1 ,2 ]
机构
[1] Natl Inst Pharmaceut Educ & Res NIPER Hajipur, Dept Pharmacol & Toxicol, Export Promot Ind Pk EPIP,Zandaha Rd,NH322, Hajipur 844102, Bihar, India
[2] Natl Inst Pharmaceut Educ & Res NIPER Kolkata, 168 Maniktala Main Rd, Kolkata 700054, W Bengal, India
[3] Inst Post Grad Ayurved Educ & Res, 294-3-1,APC Rd, Kolkata 700009, W Bengal, India
关键词
Diabetic nephropathy; Pathophysiology; End-stage renal disease; Renin-angiotensin system; Urinary albumin excretion; ALDOSE REDUCTASE INHIBITOR; RENIN-ANGIOTENSIN SYSTEM; URINARY ALBUMIN EXCRETION; ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS; OXIDATIVE STRESS; RENAL-DISEASE; NADPH OXIDASE; HIGH GLUCOSE; REDUCES MICROALBUMINURIA;
D O I
10.1016/j.lfs.2021.119635
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Diabetic nephropathy (DN), a persistent microvascular problem of diabetes mellitus is described as an elevated level of albumin excretion in urine and impaired renal activity. The morbidity and mortality of type-1 diabetics and type-2 diabetics due to end stage renal disease is also a result of the increased prevalence of DN. DN typically occurs as a consequence of an association among metabolic and hemodynamic variables, activating specific pathways leading to renal injury. According to current interventions, intensive glucose regulation decreases the threat of DN incidence and growth, and also suppressing the renin-angiotensin system (RAS) is a significant goal for hemodynamic and metabolism-related deformities in DN. However, the pathogenesis of DN is multifactorial so novel approaches other than glucose and blood pressure control are required for treatment. This review briefly summarizes the reported pathogenesis of DN, current interventions for its treatment, and possible novel interventions to unweave the thread of DN.
引用
收藏
页数:10
相关论文
共 144 条
  • [1] Abe Hideharu, 2011, Rinsho Byori, V59, P179
  • [2] Abe M, 2011, J ATHEROSCLER THROMB, V18, P1018
  • [4] Standards of Medical Care in Diabetes-2014
    不详
    [J]. DIABETES CARE, 2014, 37 : S14 - S80
  • [5] Endothelin Blockade in Diabetic Kidney Disease
    Anguiano, Lidia
    Riera, Marta
    Pascual, Julio
    Jose Soler, Maria
    [J]. JOURNAL OF CLINICAL MEDICINE, 2015, 4 (06) : 1171 - 1192
  • [6] [Anonymous], 2014, DIABETES CARE, V37 (Suppl 1), pS81, DOI [DOI 10.2337/dc14-S081, 10.2337/dc14-S081]
  • [7] DNA damage and plasma antioxidant indices in Bangladeshi type 2 diabetic patients
    Arif, M.
    Islam, M. R.
    Waise, T. M. Z.
    Hassan, F.
    Mondal, S. I.
    Kabir, Y.
    [J]. DIABETES & METABOLISM, 2010, 36 (01) : 51 - 57
  • [8] Ayodele OE, 2004, J NATL MED ASSOC, V96, P1445
  • [9] Rosiglitazone reduces urinary albumin excretion in type II diabetes
    Bakris, G
    Viberti, G
    Weston, WM
    Heise, M
    Porter, LE
    Freed, MI
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (01) : 7 - 12
  • [10] NF-κB in Renal Inflammation
    Belen Sanz, Ana
    Dolores Sanchez-Nino, Maria
    Mario Ramos, Adrian
    Antonio Moreno, Juan
    Santamaria, Beatriz
    Ruiz-Ortega, Marta
    Egido, Jesus
    Ortiz, Alberto
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (08): : 1254 - 1262